2025 Life Science E-Club Workshop Series Part 1

In parallel with the scientific roadmap of drug discovery and development, acommercial roadmapalso plays a critical role. While commercialization and product launch may seem like separate domains for scientists and startup founders, adopting acommercial mindsetearly on is essential for success.

So, what aspects of commercialization should I be aware of?

• If you are a translational scientist, how does commercialization connect with clinical development? What commercial considerations should you keep in mind when developing aTarget Product Profile (TPP)? How do you translatescientific differentiationintoclinical differentiation—and ultimately,commercial differentiation?

• If you are a startup founder, what commercial value should you highlight in your pitch deck? How do you generate key insights, such asmarket analysis?

• If you are a biotech executive, how do commercial considerations influence overallcompany strategy?

• Or perhaps you are simply interested in exploring a career in the commercial side of biotech and pharma!

9:30 - 10:00 AM| Check-in & Networking

10:00 - 11:00 AM| Fireside Chat: Understanding Key Commercial Concepts – What Do These Terms Really Mean?

11:00 - 12:00 PM| Panel Discussion: Commercial positioning, Market Research, Forecasting, Marketing, Market Access, Medical Affairs, and Pricing

12:00 - 1:00 PM| Lunch & Networking

Speaker:

Alvin Lin, MBA

Alvin (Al) Lin is Vice President of Commercial Strategy at Vera Therapeutics. His experience includes lifecycle leader, new product planning, portfolio management, BD valuations, market access, marketing, field sales, and commercial operations. He has commercialized medicines including IMBRUVICA (ibrutinib) and SOLIRIS (eculizumab) and has launched multiple products into US and exUS markets. He has worked in the past at Merck, Pharmacyclics, and Alexion, and has degrees from Cornell, MIT, and the Tufts School of Medicine.

Connie Tat, Ph.D.

Senior Medical Science Director, Oncology

Genentech

Connie is a strategic operator with nearly a decade of broad experiences across discovery, development and commercialization at globally successful biotech/biopharma companies. She specializes in oncology therapeutics within the healthcare ecosystem and has led regional cross functional teams on the commercialization of LUMAKRAS at Amgen. At Genentech, she set the strategic direction of the US GU portfolio and advanced the execution of clinical trials and collaborations. Connie trained as a scientist and previously worked in equity research and consulting focused on early to late stage biotech/biopharma. She is passionate about translating innovative scientific discoveries into commercial products that impact patient lives. She is also a speaker and advisor to the biotech startup community.

Jennifer Shen, MD, MS

Jennifer Shen is a physician scientist with extensive experience in both buy-side and sell-side business development. She also previously worked as a corporate venture investor at AstraZeneca, where she contributed to two Series A investments and spin-out deals, managed a $2 billion equity portfolio across 30 public companies, and served as a board observer for two stealth clinical stage biotech companies. Prior to AZ, Jennifer also held a role as a biotech equity researcher at the investment bank Needham and Co, responsible for IPOs of Moderna, Vaxcyte, and Pathom.

Jennifer held a decade-long career as a medical professional and scientific researcher where earned an M.S. and completed a postdoctoral research fellowship at Stanford, followed by an M.D. from SUNY Buffalo. She also worked as a general surgery intern at USC and anesthesia resident at New York Medical College.

Event Venue & Nearby Stays

1633 Old Bayshore Hwy #280, 1633 Old Bayshore Highway, Burlingame, United States